Exagen (XGN) to Release Quarterly Earnings on Tuesday

Exagen (NASDAQ:XGN - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Tuesday, July 29th. Analysts expect Exagen to post earnings of ($0.18) per share and revenue of $16.25 million for the quarter.

Exagen (NASDAQ:XGN - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, meeting analysts' consensus estimates of ($0.20). Exagen had a negative net margin of 27.34% and a negative return on equity of 133.69%. The firm had revenue of $15.50 million during the quarter, compared to analyst estimates of $14.55 million. During the same period in the previous year, the business earned ($0.19) EPS. On average, analysts expect Exagen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Exagen Price Performance

NASDAQ:XGN traded down $0.05 during midday trading on Friday, hitting $7.18. The company had a trading volume of 42,478 shares, compared to its average volume of 209,369. The stock's fifty day moving average price is $6.95 and its 200-day moving average price is $5.22. The company has a quick ratio of 2.32, a current ratio of 2.32 and a debt-to-equity ratio of 2.87. Exagen has a 52-week low of $1.78 and a 52-week high of $7.95. The company has a market capitalization of $152.83 million, a PE ratio of -8.54 and a beta of 1.58.

Hedge Funds Weigh In On Exagen

A hedge fund recently bought a new stake in Exagen stock. Acadian Asset Management LLC purchased a new position in shares of Exagen Inc. (NASDAQ:XGN - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 6,984 shares of the company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 75.25% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on XGN. UBS Group reaffirmed an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. Canaccord Genuity Group lifted their price objective on shares of Exagen from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Tuesday, May 13th. Cantor Fitzgerald dropped their price target on shares of Exagen from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. BTIG Research restated a "buy" rating on shares of Exagen in a report on Wednesday, May 7th. Finally, Craig Hallum initiated coverage on shares of Exagen in a report on Wednesday. They issued a "buy" rating and a $12.00 price target for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Exagen has a consensus rating of "Buy" and a consensus target price of $9.00.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).